On April 25, 2023, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2023 clinical practice guideline amendment for the management of advanced prostate cancer. This guideline contains a total of 40 recommendations, and the revision includes updates to recommendations under these disease states:
- Biochemical recurrence (“rising PSA state”) without metastatic disease when all local therapy options have been exhausted
- Metastatic hormone-sensitive prostate cancer
- Non-metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer